|
M.G. Pavlova
Vildagliptin - new opportunities in the treatment of type 2 diabetes mellitus
|
№11-12 / 2022
|
|
A.E. Bagriy, E.S. Mikhailichenko, A.V. Prikolota, K.E. Mogilevskaya
Features of the pathogenesis and treatment of diabetes mellitus during the COVID-19 pandemic
|
№11-12 / 2022
|
|
P.B. Shorokhova, V.L. Baranov, N.V. Vorokhobina, O.S. Shpilevaya
Genetic predictors of the pharmacological effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in patients with type 2 diabetes mellitus
|
№4 / 2019
|
|
N.A. Petunina, A.L. Terekhova
ELDERLY PATIENT WITH TYPE 2 DIABETES MELLITUS: FOCUS ON ALOGLIPTIN
|
№5 / 2017
|
|
M.B. Antsiferov (1), V.V. Fadeev (2), T.B. Morgunova (2)
MODERN APPROACHES TO THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№16 / 2016
|
|
M.B. Antsiferov
APPLICATION OF SAXAGLIPTIN AND ITS COMBINATION WITH METFORMIN IN THE THERAPY OF TYPE 2 DIABETES MELLITUS IN ELDERLY PATIENTS
|
№5 / 2016
|
|
A.S. Ametov (1), N.A. Chernikova (1), T.Yu. Demidova (1), P.K. Nazhmutdinova (2)
GLYCEMIC VARIABILITY AS A THERAPEUTIC TARGET IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№5 / 2016
|
|
A.S. Ametov
ADVANTAGES OF FIXED COMBINATION OF SAXAGLIPTIN AND METFORMIN WITH MODIFIED RELEASE (KOMBOGLYCE PROLONG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2015
|
|
А.А. Yuryatin
THE SAVOR TRIAL: THE BEGINNING OF THE NEW ERA OF SAFE PHARMACOTHERAPY FOR TYPE-2 DIABETES MELLITUS
|
№5 / 2014
|
|
A.S. Ametov
ADVANTAGES OF THE NEW FIXED COMBINATION OF SAXAGLIPTIN AND TIME-RELEASE METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
|
№16 / 2013
|
|
L.A.Ruyatkina, D. S. Ruyatkin, G.A.Berezovskaya
HYPOGLYCEMIA IN THE PATHOGENESIS OF CARDIOVASCULAR RISK
|
№6 / 2013
|
|
M.B. Antsiferov 1, G.R. Galstyan 2
Administration Of Antidiabetic Drug To Patients – What Is Necessary, Except Prescription?
|
№16 / 2012
|
Русский
